Analysts Anticipate Cellular Biomedicine Group Inc (CBMG) Will Post Earnings of -$0.53 Per Share

Share on StockTwits

Equities analysts expect Cellular Biomedicine Group Inc (NASDAQ:CBMG) to announce earnings per share (EPS) of ($0.53) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Cellular Biomedicine Group’s earnings, with the highest EPS estimate coming in at ($0.50) and the lowest estimate coming in at ($0.55). Cellular Biomedicine Group also posted earnings per share of ($0.53) in the same quarter last year. The firm is expected to issue its next earnings report on Wednesday, August 14th.

According to Zacks, analysts expect that Cellular Biomedicine Group will report full-year earnings of ($2.09) per share for the current fiscal year, with EPS estimates ranging from ($2.28) to ($1.90). For the next year, analysts expect that the business will report earnings of ($1.97) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Cellular Biomedicine Group.

Cellular Biomedicine Group (NASDAQ:CBMG) last issued its quarterly earnings data on Tuesday, February 19th. The biotechnology company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.01). The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.05 million. Cellular Biomedicine Group had a negative net margin of 17,921.62% and a negative return on equity of 42.41%.

Several equities research analysts have issued reports on the stock. BidaskClub lowered shares of Cellular Biomedicine Group from a “buy” rating to a “hold” rating in a research report on Friday, April 19th. Robert W. Baird assumed coverage on shares of Cellular Biomedicine Group in a research report on Wednesday, February 6th. They set an “outperform” rating and a $26.00 target price for the company. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $27.67.

NASDAQ:CBMG traded up $0.26 during mid-day trading on Wednesday, hitting $16.34. 744 shares of the stock traded hands, compared to its average volume of 31,649. The stock has a market cap of $275.14 million, a P/E ratio of -8.01 and a beta of 2.81. Cellular Biomedicine Group has a 12-month low of $12.04 and a 12-month high of $25.00.

Several institutional investors and hedge funds have recently made changes to their positions in CBMG. Platinum Investment Management Ltd. bought a new stake in shares of Cellular Biomedicine Group in the 1st quarter worth approximately $11,309,000. Nikko Asset Management Americas Inc. bought a new stake in shares of Cellular Biomedicine Group in the 1st quarter worth approximately $6,721,000. Sumitomo Mitsui Trust Holdings Inc. bought a new stake in shares of Cellular Biomedicine Group in the 1st quarter worth approximately $6,622,000. ARK Investment Management LLC bought a new stake in shares of Cellular Biomedicine Group in the 1st quarter worth approximately $4,944,000. Finally, BlackRock Inc. lifted its holdings in shares of Cellular Biomedicine Group by 7.7% in the 3rd quarter. BlackRock Inc. now owns 634,006 shares of the biotechnology company’s stock worth $11,508,000 after acquiring an additional 45,154 shares during the last quarter. Hedge funds and other institutional investors own 11.36% of the company’s stock.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.

Featured Story: How accurate is the Rule of 72?

Get a free copy of the Zacks research report on Cellular Biomedicine Group (CBMG)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with's FREE daily email newsletter.